Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Executive Summary
The Global Multiple Sclerosis Market is estimated at USD 26.01 Billion in the year 2020. The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market. Various technological advancements, such as the development of innovative monoclonal bodies, immuno-modulators, immunosuppressants and interferons for the effective treatment of MS, are acting as major growth-inducing factors. Moreover, the growth of the global multiple sclerosis market is driven by a shift in preference toward oral drugs. Also, an increase in the number of pipeline drugs is anticipated to offer lucrative opportunities for market expansion during the forecast period.
The expansion of the Multiple Sclerosis Market is encouraged by government and non-government organizations. The government and non-governmental organizations support a variety of initiatives and programs to help persons with multiple sclerosis improve their quality of life (MS).
The global multiple sclerosis market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. In addition, clinical studies for the treatment of multiple sclerosis are being conducted by several pharmaceutical companies. Companies are working to create novel medicines in multiple sclerosis radiology for patients suffering from the condition which is further driving the growth of the market.
Scope of the Report
• The report analyses the Multiple Sclerosis Market for the historical period 2016-2020 and the forecast period of 2021-2026.
• The report analyses the Multiple Sclerosis Market by Value (USD Million).
• The report analyses the Multiple Sclerosis Market Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others).
• The report analyses the Multiple Sclerosis Market by Route of Administration (Oral, Injectable, Intravenous).
• The report analyses the Multiple Sclerosis Market Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
• The Global The report analyses the Multiple Sclerosis Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
• Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India, South Korea).
• The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Drug Class, by Route of Administration, by Distribution Channel.
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, Pipelines and new product development. The companies analysed in the report include Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Pfizer Inc., GlaxoSmithKline, Novartis AG, Teva Pharmaceuticals Industries Limited, BAYER AG, Biogen, EMD Sereno, NervGen Pharma.
Key Target Audience
• Healthcare and Pharmaceutical Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Multiple Sclerosis Market: Product Outlook
4. Global Multiple Sclerosis Market: Sizing and Forecast
4.1 Global Multiple Sclerosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Multiple Sclerosis Market
5. Global Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel
5.1 Competitive Scenario of Global Multiple Sclerosis Market: By Drug Class
5.1.1 Immunomodulators - Market Size and Forecast (2016-2026)
5.1.2 Immunosuppressants - Market Size and Forecast (2016-2026)
5.1.3 Interferons - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Multiple Sclerosis Market: By Route of Administration
5.2.1 Oral - Market Size and Forecast (2016-2026)
5.2.2 Injectable - Market Size and Forecast (2016-2026)
5.2.3 Intravenous - Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Multiple Sclerosis Market: By Distribution Channel
5.3.1 Hospitals Pharmacy- Market Size and Forecast (2016-2026)
5.3.2 Retail Pharmacy - Market Size and Forecast (2016-2026)
5.3.3 Online Pharmacy - Market Size and Forecast (2016-2026)
6. Global Multiple Sclerosis Market: Regional Analysis
6.1 Competitive Scenario of Global Multiple Sclerosis Market: By Region
7. North America Multiple Sclerosis Market: An Analysis (2016-2026)
7.1 North America Multiple Sclerosis Market: Size and Forecast (2016-2026)
7.2 North America Multiple Sclerosis Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
7.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
7.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
7.6 North America Multiple Sclerosis Market: Country Analysis
7.7 Market Opportunity Chart of North America Multiple Sclerosis Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Multiple Sclerosis Market: By Country
7.9 United States Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.10 United States Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
7.11 Canada Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
7.12 Canada Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8. Europe Multiple Sclerosis Market: An Analysis (2016-2026)
8.1 Europe Multiple Sclerosis Market: Size and Forecast (2016-2026)
8.2 Europe Multiple Sclerosis Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
8.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
8.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
8.6 Europe Multiple Sclerosis Market: Country Analysis
8.7 Market Opportunity Chart of Europe Multiple Sclerosis Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Multiple Sclerosis Market: By Country
8.9 Germany Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.10 Germany Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.11 United Kingdom Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.13 France Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.14 France Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
8.15 Italy Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
8.16 Italy Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9. Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Multiple Sclerosis Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Immunomodulators, Immunosuppressants, Interferons and Others)
9.4 Market Segmentation By Route of Administration (Oral, Injectable, Intravenous)
9.5 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
9.6 Asia Pacific Multiple Sclerosis Market: Country Analysis
9.7 Market Opportunity Chart Asia Pacific Multiple Sclerosis Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Multiple Sclerosis Market: By Country
9.9 China Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.10 China Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
911 Japan Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.12 Japan Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.13 India Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.14 India Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
9.15 South Korea Multiple Sclerosis Market: Size and Forecast (2016-2026), By Value
9.16 South Korea Multiple Sclerosis Market Segmentation - By Drug Class, By Route of Administration, By Distribution Channel (2016-2026)
10. Global Multiple Sclerosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Drug Class, 2026
11.1 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Route of Administration, 2026
11.2 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Distribution Channel, 2026
11.3 Market Attractiveness Chart of Global Multiple Sclerosis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Multiple Sclerosis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 Bristol-Myers Squibb
13.2 F. Hoffman-La Roche, Ltd.
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Teva Pharmaceuticals Industries Limited
13.7 BAYER AG
13.8 Biogen
13.9 EMD Sereno
13.10 NervGen Pharma
Request Sample 
Request Discount 
Inquire Before Buy
